Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Authors

Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai, Patrice Herait, Carmen Kahatt, François Lokiec, Gilles Salles, Thierry Facon, Antonio Palumbo, David Cunningham, Emanuele Zucca, Catherine Thieblemont